Compare Inovio Pharmaceuticals Inc (INO) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Koninklijke Philips NV — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Koninklijke Philips NV trades at $26.61 (market cap $26.19B). The key difference: Koninklijke Philips NV is far larger — about 293.4× Inovio Pharmaceuticals Inc's market cap, and Koninklijke Philips NV pays a 3.79% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | PHG | |
|---|---|---|
Market Cap | $89.27M | $26.19B |
Sector | Health | Health |
52-Week High | $2.87 | $32.91 |
52-Week Low | $1.05 | $24.54 |
Enterprise Value | $60.28M | $32.46B |
Dividend Yield | — | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
PHG trades at $26.80, down 0.56% with bearish technical signals. The company shows improved fundamentals with net income turning positive to $895M in 2025 after previous losses, though revenue declined slightly to $17.83B. Analyst consensus is mixed with 40.9% buy ratings but technical indicators show selling pressure. Recent developments include FDA clearances for AI-powered medical devices and strategic healthcare partnerships.
PHG presents a turnaround story with profitability recovery but faces execution risks amid competitive pressures. The stock offers value at reasonable valuations (P/E 23.67, P/S 1.29) but requires monitoring of revenue stabilization and AI product adoption. Near-term catalyst includes Q2 2026 earnings with expected EPS of $0.40.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
